PT-141, also known by its generic name bremelanotide and its brand name Vyleesi, is one of the very few peptide drugs that acts not on a peripheral tissue but on the brain itself. Unlike sildenafil (Viagra) and the rest of the PDE5 inhibitor class, which produce their effect through vasodilation in the penis, PT-141 works centrally—activating melanocortin receptors in the hypothalamus that are part of the neural machinery controlling sexual desire and arousal. That mechanism is what makes PT-141 legitimately interesting and also what makes it uniquely complicated, because brain-level pharmacology is rarely as predictable or as targeted as peripheral pharmacology.
PT-141 is FDA-approved for one specific indication: hypoactive sexual desire disorder (HSDD) in premenopausal women. That single indication sits inside a much larger off-label and gray-market ecosystem involving men, recreational users, and the adjacent—but very different—melanotan peptides sold for tanning. In this deep dive we separate the clinical science from the gray market and explain what PT-141 actually is, where it came from, what it does, and where its risks live.
⚕️ Regulatory notice: PT-141/bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. All other use—male sexual dysfunction, post-menopausal women, recreational use, research-chemical PT-141 from online vendors—is off-label or unregulated. Peptides sold as "PT-141" outside the prescription pathway have no verified identity, purity, or dose accuracy, and some have been associated with severe blood pressure spikes. This article is educational and not medical advice.
What Is PT-141?
PT-141 is a synthetic cyclic heptapeptide derived from α-melanocyte-stimulating hormone (α-MSH), the 13-amino-acid peptide that in native biology regulates skin pigmentation, appetite, and—critically—central nervous system reward and sexual function pathways. The history of PT-141 starts with a much earlier experimental peptide called melanotan II, which was developed in the 1980s at the University of Arizona by Mac Hadley, Victor Hruby, and colleagues who were exploring α-MSH analogs for skin protection against UV damage. During early human testing of melanotan II, volunteers reported an unexpected side effect: spontaneous erections and increased sexual arousal.
That observation led Palatin Technologies to spin off a program focused on the sexual-function effect rather than the tanning effect. They engineered bremelanotide—a cyclic peptide with key substitutions that shifted its receptor profile toward the melanocortin 4 receptor (MC4R), the subtype most strongly implicated in central control of sexual behavior, while reducing activity at the melanocortin 1 receptor (MC1R) responsible for skin pigmentation.
The drug was originally tested as an intranasal formulation for male erectile dysfunction, but development for that indication was halted in 2008 after reports of significant blood pressure increases. Palatin reformulated bremelanotide as a subcutaneous injection and pursued the female HSDD indication, leading to FDA approval in June 2019 as Vyleesi.
Vyleesi is administered as a single-use autoinjector, dosed on-demand approximately 45 minutes before anticipated sexual activity, not more than once per 24 hours and not more than eight times per month.
Mechanism of Action
PT-141 binds and activates melanocortin receptors—primarily MC4R, with secondary activity at MC1R and MC3R. MC4R is densely expressed in the hypothalamus, particularly in the paraventricular nucleus, which is a key integrator of sexual, appetitive, and stress signals. Activation of MC4R in this region increases firing of oxytocin-producing neurons and modulates dopaminergic reward circuits implicated in sexual desire.
The key contrast with PDE5 inhibitors is worth stating clearly:
| Drug class | Site of action | Mechanism | Clinical effect |
|---|---|---|---|
| PDE5 inhibitors (Viagra, Cialis) | Penile vasculature (periphery) | Increase cGMP → smooth muscle relaxation → blood flow | Enables erection if desire is present |
| PT-141 / bremelanotide | Hypothalamus (central brain) | Activates MC4R → modulates sexual desire circuits | Increases desire and arousal itself |
In other words, PDE5 inhibitors fix the plumbing. PT-141 touches the wiring. That distinction is what makes it useful in HSDD, where the problem is not mechanical arousal but the upstream motivational state, and it is also what makes PT-141 more prone to unpredictable, highly individual responses—because brain circuits are more complex than vascular smooth muscle.
MC4R activation also has well-known off-target effects. The same receptor is involved in appetite regulation (which is why MC4R agonists like setmelanotide are approved for rare genetic obesity). And because melanocortin signaling extends to blood pressure control and skin pigmentation, PT-141 produces predictable side effects in those domains.
The Clinical Evidence
The pivotal FDA approval of Vyleesi rested on two Phase 3 trials, RECONNECT (NCT02333071 and NCT02338960), with combined enrollment of about 1,247 premenopausal women with acquired, generalized HSDD. Results were published by Kingsberg, Clayton, and colleagues in Obstetrics & Gynecology (2019) and summarized in the FDA approval review.
Key findings:
- At 24 weeks, women treated with PT-141 showed statistically significant improvements vs. placebo on the Female Sexual Function Index desire score and the Female Sexual Distress Scale–Desire/Arousal/Orgasm score.
- The magnitude of the effect was modest: treatment–placebo differences were statistically significant but clinically small. Only ~25% of women on PT-141 achieved a clinically meaningful improvement on both co-primary endpoints, versus ~17% on placebo.
- Discontinuation due to adverse events was about 18% in the treatment arms.
- The most common adverse effects were nausea (40%, often severe enough to require anti-nausea premedication), flushing, injection-site reactions, headache, and transient increases in blood pressure.
Earlier male erectile dysfunction trials (nasal spray formulation) had shown efficacy but were halted in 2008 because of sustained, clinically meaningful blood pressure elevations—an effect that continues to appear in post-marketing data for the subcutaneous formulation.
The honest summary: Vyleesi works, but the effect size is small, tolerability is a real issue, and the drug has never shown outcomes competitive with—for example—adequately treating depression, relationship therapy, or addressing hormonal contributors to low desire.
Applications and Use Cases
- On-label: Hypoactive sexual desire disorder in premenopausal women, as on-demand subcutaneous injection.
- Off-label (common): Male erectile dysfunction in PDE5-inhibitor non-responders; female arousal concerns outside the HSDD diagnostic box; post-menopausal women (despite trial exclusion).
- Gray-market / research-chemical: Recreationally, often in combination with PDE5 inhibitors, usually via unregulated vials that bypass prescription.
Clinicians who use PT-141 off-label generally advise low test doses, monitoring of blood pressure, and strict avoidance in anyone with uncontrolled hypertension or cardiovascular disease.
Connection to Gene Editing
The melanocortin pathway is also one of the cleanest examples of how human genetics drives both drug development and gene-editing strategy. Loss-of-function mutations in MC4R cause a form of severe monogenic obesity; the FDA-approved drug setmelanotide (Imcivree) was developed specifically to treat these patients by agonizing MC4R. That is almost exactly the same target PT-141 hits, just with a different clinical context.
Gene editing enters the picture in two ways. First, diagnostic: CRISPR-based gene panels are now standard for identifying rare MC4R-pathway obesity patients who may be candidates for setmelanotide. Second, therapeutic: researchers have explored the possibility of correcting loss-of-function POMC and MC4R mutations directly via base editing or prime editing, which would offer a durable alternative to lifelong peptide therapy. That path is still preclinical, but it illustrates how a peptide drug and a gene-editing program can sit on the same pathway, one acting pharmacologically and the other at the genome.
For more on how disease genetics shapes targets, see our CRISPR complete guide.
Limitations and Regulatory Status
- Approved only in premenopausal women for HSDD. All other use is off-label or unregulated.
- Transient blood pressure increase. Typical elevations of 6 mmHg systolic and 3 mmHg diastolic within 1–4 hours. Individuals with uncontrolled hypertension or cardiovascular disease should not use it.
- Nausea. Very common, sometimes severe.
- Focal hyperpigmentation and darkening of existing moles. Because PT-141 still has residual MC1R activity, skin pigmentation changes and darkening of nevi can occur. Any changes in existing moles should be medically evaluated.
- Confusion with melanotan peptides. Melanotan I (afamelanotide, approved for erythropoietic protoporphyria under the brand Scenesse) and melanotan II (unapproved, widely sold on the gray market for tanning) are chemically related but clinically and legally distinct from bremelanotide. Melanotan II in particular has been associated with serious adverse events and is not FDA-approved for any use.
- Cost and access. Vyleesi is expensive; on-demand use over time runs thousands of dollars per year.
Frequently Asked Questions
Is PT-141 the same as Viagra?
No. Viagra (sildenafil) is a small-molecule PDE5 inhibitor that works peripherally on penile blood flow. PT-141 is a peptide that works centrally in the brain on melanocortin receptors involved in desire and arousal.
Is PT-141 approved for men?
No. Vyleesi is approved only for hypoactive sexual desire disorder in premenopausal women. Male use is off-label.
Is PT-141 the same as melanotan?
They are related—PT-141 is derived from the same α-MSH family as melanotan II—but PT-141 was engineered to minimize tanning effects and was developed through legitimate FDA trials. Melanotan I (afamelanotide) is approved for a rare photosensitivity disorder. Melanotan II is not approved for any use.
Can PT-141 damage skin or moles?
Yes, it can cause focal hyperpigmentation and darkening of existing moles. Any rapid change in a mole should be evaluated by a dermatologist to rule out melanoma.
Does PT-141 raise blood pressure?
Yes, transiently. Typical increases are modest but can be clinically meaningful, and the drug is contraindicated in patients with uncontrolled hypertension or cardiovascular disease.
How long does PT-141 take to work?
The approved protocol is subcutaneous injection 45 minutes before anticipated sexual activity. Individual response varies.
